Prime editing

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Retrieved on: 
Tuesday, April 23, 2024
Chronic granulomatous disease, CGD, Cell, Conference, Society, Prime editing, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at the 3rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024); the American Society of Cell & Gene Therapy 27th Annual Meeting (Baltimore, May 7-11, 2024); and TIDES USA Oligonucleotide & Peptide Therapeutics Conference (Boston, May 14-17, 2024).

Key Points: 
  • “In the short time since Prime Editing was first discovered, we have made incredible strides advancing this technology, developing and optimizing Prime Editors for programs across our core areas of focus, and creating new delivery systems that we believe will permit our Prime Editors to safely and effectively access target tissue,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
  • In addition to our presentations, we congratulate our Co-Founder, David Liu, on receiving the ASGCT Outstanding Achievement Award, highlighting his work in the gene editing field, including his contributions to the discovery and advancement of Prime Editing.
  • We look forward to coming together with the scientific research community and highlighting our leading position in the field of next-generation gene editing.”
    Details of the presentations are as follows.
  • Presentation Name: Advancing LNP Screening to Incorporate Automated, High-Throughput Readouts

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, November 3, 2023
Gene editing, International Symposium on Endovascular Therapy, FDA, Research, Food, Rhodopsin, Human, Congress, Fragile X syndrome, G&A, Liver, CFTR, Chromosomal translocation, Regulation of tobacco by the U.S. Food and Drug Administration, Cell, Initial, R, Society, ASH, RHO, Tissue, Lung, Cystic fibrosis, Prime editing, Gene, Composition, Abstract, LNP, Eye, Safety, European Society of Clinical Microbiology and Infectious Diseases, Investment, CGD, Patient, Retina, NHP, Patent, D, Vaccine, Pharmaceutical industry, Fine chemical, Beef cattle, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

Key Points: 
  • 11,795,452 --
    CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
  • Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
  • In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
  • Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Retrieved on: 
Tuesday, October 17, 2023
Palilalia, LNP, CFTR, Liver disease, Safety, Hotspot, Cystic fibrosis, Prime editing, Science, Lung, Patient, Pharmaceutical industry, Vaccine

Title: Prime Editing in Hematopoietic Diseases and Beyond: Efficacy and Safety

Key Points: 
  • Title: Prime Editing in Hematopoietic Diseases and Beyond: Efficacy and Safety
    Overview of Prime Medicine’s comprehensive proprietary approach to off-target analysis, including details of off-target analyses from Prime Medicine’s programs.
  • First in vivo proof-of-concept data in adRP, including mutational hotspot Prime Editing, initial safety data for lead Retinitis Pigmentosa program, and highlights from Prime Medicine’s modular retinal delivery platform.
  • Prime Medicine’s liver-targeted LNP and all-RNA delivery platforms, in vivo proof-of-concept data, and first non-human primate data for Prime Editing in GSD1b.
  • Additional data from Prime Medicine’s liver-targeted LNP and all-RNA delivery platforms; in vivo proof-of-concept data in GSD1b program; and expanded non-human primate results for Prime Editing in GSD1b.

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, August 7, 2023
Myelodysplastic syndrome, Exercise, Chronic granulomatous disease, Partnership, Gene, SCIP, Eye, Immunotherapy, G&A, Toxicity, Research, Economics, CD34, Acute myeloid leukemia, Transplant, MDS, Health, AML, Investment, Patient, Cancer, Annual general meeting, Cell, CGD, American Society of Gene and Cell Therapy, Liver, Prime editing, HSC, R, Therapy, CD117, Society, DSM-IV codes, D, Medical device, Pharmaceutical industry, Vaccine, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the second quarter ended June 30, 2023.

Key Points: 
  • In May 2023, Prime Medicine presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Initiate investigational new drug (IND)-enabling studies for PM359 in CGD in 2023.
  • Maximize Prime Editing’s broad therapeutic potential and create value through strategic business development that extends the reach and impact of Prime Editing to areas beyond Prime Medicine’s current areas of focus.
  • Second Quarter 2023 Financial Results:
    R&D Expenses: Research and development (R&D) expenses were $34.6 million for the three months ended June 30, 2023, as compared to $18.9 million for the three months ended June 30, 2022.

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

Retrieved on: 
Tuesday, August 1, 2023
Tissue, LSE, DNA, Partnership, Gene editing, Patient, Prime editing, Cell engineering, DSM-IV codes, Pharmaceutical industry, Vaccine

Under the terms of the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • “We are pleased to partner with Prime Medicine and support their breakthrough gene editing technology,” said Doug Doerfler, President and CEO of MaxCyte.
  • The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies.
  • Prime Medicine is MaxCyte’s 23rd strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

Retrieved on: 
Thursday, June 22, 2023
Myelodysplastic syndrome, Exercise, Mouse, Partnership, Radiation, ASH, SCIP, Biotechnology, Gene editing, Beta thalassemia, Malignancy, Toxicity, Research, Cell, Economics, Acute myeloid leukemia, Health, Transplant, MDS, AML, Patient, Risk, Sickle, Protein engineering, Sickle cell disease, Prime editing, HSC, CD117, Therapy, Society, DSM-IV codes, Safety, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass. and BASEL, Switzerland, June 22, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, and Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, today announced a research collaboration to combine their respective technologies, including Prime Medicine’s Prime Editing platform and Cimeio’s Shielded Cell and Immunotherapy Pairs (SCIP) platform.

Key Points: 
  • Cimeio’s SCIP platform combined with Prime Editing may significantly improve the accessibility, eligibility and outcomes for patients who could benefit from HSC transplant.
  • These combined technologies may also enable selection of in vivo edited HSCs, which could allow for the treatment of genetic diseases without a transplant.
  • If the research collaboration is successful, the companies will grant exclusive license options to each other for their technology.
  • We look forward to partnering with the extremely talented team at Prime Medicine to advance our novel CD117 program.”

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, May 11, 2023
Spark Therapeutics, Chronic granulomatous disease, Intellectual property, Patent, Pfizer, Bleeding, Gene, CHOP, Eye, Food and Drug Administration, RNA, G&A, Retina, Sale, Novartis, Investment, Patient, Cancer, Annual general meeting, Cell, CGD, American Society of Gene and Cell Therapy, Liver, Prime editing, R, Research, Therapy, Society, Food, DSM-IV codes, D, Management, Cryptocurrency, Pharmaceutical industry, Vaccine, Video game, Spark, IND

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the first quarter ended March 31, 2023.

Key Points: 
  • 17/751,599 --
    -- Cash, cash equivalents, investments and restricted cash balance of $263.0 million as of March 31, 2023 --
    CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the first quarter ended March 31, 2023.
  • In April 2023, Prime Medicine received a notice of allowance from the U.S. PTO for its third patent application, No.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Initiate investigational new drug (IND)-enabling studies for PM359 in CGD in 2023.
  • Maximize Prime Editing’s broad therapeutic potential and create value through strategic business development that extends the reach and impact of Prime Editing to areas beyond Prime Medicine’s current areas of focus.

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Disease, FRDA, Genome, Cystic fibrosis transmembrane conductance regulator, Swelling, CGD, Safety data sheet, Respiratory tract, GAA, Tissue, Cystic fibrosis, CD34, CMC, AAV, Heart, Failure rate, CFTR, Mitochondrion, Culture, DNA, LNP, Safety, Mutation, IPSC, Gene editing, Central nervous system, Hepatocyte, Patient, Degenerative disease, CF, Bronchiole, Neuron, PCSK9, Ataxia, Liver, Human, FXN, Inflammation, Chronic granulomatous disease, Eye, Investment, Prime editing, Vaccine, Pharmaceutical industry, Medical device, IND, WD, Frataxin

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.

Key Points: 
  • Today, Prime Medicine announced new preclinical data demonstrating that Prime Editing-mediated removal of pathological repeats in vitro results in correction of hypermethylation at the FXN gene, restoring genetic function back to wild-type levels.
  • Off-target Safety Data: Prime Medicine is progressing a comprehensive suite of assays to evaluate the potential off-target activity of its Prime Editors.
  • Prime Medicine is using PCSK9 as a model system for developing its modular LNP delivery platform to the liver.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Nominate first development candidate for CGD in 1Q 2023.

Prime Medicine Announces Closing of Upsized Initial Public Offering

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Prime editing, Sale, Telephone, Varick Street, LLC, Jefferies Group, Patient, Broadridge Financial Solutions, Gene editing, Madison Avenue, Security (finance), Attention, Nasdaq, 2nd Floor (Nina song), Technology, Goldman Sachs, Exercise, Morgan Stanley, GLOBE, Prospectus, Jefferies, Forward-looking statement

CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.
  • The gross proceeds of the offering were approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses.
  • In addition, Prime Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 shares of its common stock at the initial public offering price less underwriting discounts and commissions.
  • All shares in the offering were offered by Prime Medicine.

Prime Medicine Announces Pricing of Upsized Initial Public Offering

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, U.S. Securities and Exchange Commission, Prime editing, Sale, Telephone, Varick Street, LLC, Jefferies Group, Patient, Broadridge Financial Solutions, Gene editing, Madison Avenue, Security (finance), Attention, Nasdaq, 2nd Floor (Nina song), Technology, Goldman Sachs, Morgan Stanley, Prospectus, Jefferies, Forward-looking statement

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.

Key Points: 
  • Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.
  • The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million.
  • In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.
  • J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.